公开(公告)号：US20230111568A1

公开(公告)日：2023-04-13

申请号：US17913844

申请日：2021-03-24

申请人： Bausch Health Ireland Limited

发明人： Zeev Heimanson ,  Robert J. Israel ,  Thejasvi Ramakrishna ,  Jason Lamar Vittitow

IPC分类号： A61K31/437 ,  A61P1/16 ,  A61P25/28 ,  A61K31/7016 ,  A61K9/20 ,  A61K9/28

摘要： Provided herein are solid dispersions comprising rifaximin and methods of using the same for the treatment of Overt Hepatic Encephalopathy and complications associated with cirrhosis.

公开(公告)号：US20220380449A1

公开(公告)日：2022-12-01

申请号：US17642130

申请日：2020-09-11

申请人： BAUSCH HEALTH IRELAND LIMITED

发明人： Robert J. Israel

IPC分类号： C07K16/24 ,  A61P1/16

摘要： The present disclosure is directed to a method of treating nonalcoholic fatty liver disease (NAFLD), and subsets thereof such as nonalcoholic steatohepatitis (NASH), using an IL-17 antagonist, such as a monoclonal antibody that specifically binds to IL-17 receptor A (IL-17RA).

公开(公告)号：US20220175764A1

公开(公告)日：2022-06-09

申请号：US17529818

申请日：2021-11-18

申请人： Bausch Health Ireland Limited

发明人： Lorin K. Johnson ,  XiaoJun Nicole Deng ,  William J. Jo Siu ,  Robert J. Israel ,  Zeev Heimanson

IPC分类号： A61K31/485 ,  A61K31/437 ,  A61P1/16 ,  A61P1/00

摘要： The present disclosure is directed to the use of methylnaltrexone, or a salt thereof, and rifaximin for the treatment of increased gut permeability, or an associated disorder, e.g., NASH or NAFLD.